Mimer Medical's journey towards securing a health claim for Appethyl, a spinach extract, is a testament to the challenges and potential rewards of navigating the supplement industry's regulatory maze. This Swedish-born innovation, developed by Lund University professors Charlotte Erlanson-Albertsson and her late husband Per-Åke Albertsson, has faced numerous hurdles since its inception nearly two decades ago.
The key to Appethyl's success lies in its unique composition. It is an extract enriched with thylakoids, the cellular membranes responsible for photosynthesis. These thylakoids are believed to slow down fat digestion, leading to increased production of satiety hormones GLP-1 and CCK. This mechanism sets Appethyl apart from natural GLP-1 agonist drugs, offering a 'broader' and 'gentler' impact on hunger hormones, according to Professor Jan Bruhn, Mimer Medical's senior vice president of R&D.
The road to this point has been arduous. Mimer Medical's small team of senior experts, some of whom returned from retirement for this project, faced a daunting task. The European Food Safety Authority (EFSA) received 61 health claim applications between 2010 and 2020, rejecting 55 of them. Mimer Medical's application, filed in September 2025, for the claim that 'consumption of Appethyl as part of a meal prolongs satiety and reduces cravings after that meal', has now passed the initial hurdle of being deemed valid and admissible for formal scientific review.
The five clinical trials supporting this claim, including a 2015 study covered by NutraIngredients, demonstrate Appethyl's potential. A single 5-gram dose of the spinach extract was associated with a 43% greater weight loss and an 85% reduction in cravings for unhealthy foods. These findings are particularly compelling in a market where weight management is a thriving concern.
Despite the progress, Mimer Medical's journey is not without its complexities. The company is open to acquisition offers for the Appethyl project, including patents, trademarks, and clinical and technical documentation. This decision reflects the realization that the project's success may require the expertise of a larger, more specialized team.
The story of Appethyl is a fascinating blend of scientific discovery, regulatory challenges, and market potential. It highlights the importance of perseverance and the unique advantages that natural ingredients can offer in a competitive health and wellness landscape. As Mimer Medical continues its journey, the future of Appethyl remains uncertain, but its potential to impact the satiety health claim market is undeniable.
